EPO-Hyporesponse – Strategien für eine effektive Therapie

Die Anämie bei einer chronischen Funktionseinschränkung der Niere ist multifaktoriell bedingt. Der Erythropoetinmangel ist im Zentrum der Aufmerksamkeit und der Therapie. Man muss aber die begleitenden Faktoren berücksichtigen. Ansonsten ist die EPO-Therapie unwirksam. Häufig wird die renale Anämie von Eisenmangel, Eisenverwertungsstörungen bei akuten oder chronischen Entzündungszuständen, sekundärem Hyperparathyreoidismus und weiteren, seltenen Faktoren begleitet. Diese Komponenten muss man bei einem fehlenden Ansprechen der renalen Anämie auf EPO-Gaben analysieren. Eine EPO-Hyporesponse ist definiert als ein fehlendes Ansprechen über 4–6 Monate nach der Substitution von mehr als 300 IE EPO pro kg Körpergewicht pro Woche. Die Differenzialdiagnose der EPO-Hyporesponse und die Abklärung können schematisiert erfolgen. Unter einer danach erfolgenden gezielten Behandlung ist die Substitution im Regelfall effektiv.

The causes of anemia in chronic renal failure are multiple. The deficiency of erthyropoetine is in the centre of the awareness of the caregivers. However, the accompanying factors also have to be put into account. Otherwise, failure of EPO therapy is the result. Renal anemia often is combined with iron deficiencies, iron achrestic pictures seen with acute or chronic inflammations, secondary hyperparathyreoidism and more, rare factors. These components have to be analyzed if failure of EPO therapy is diagnosed. The definition of EPO hyporesponse is as following: not reaching target hemoglobin levels after the use of more than 300 IU EPO per kg bodyweight per week for 4–6 months. The work-up of the differential diagnosis can be following a flow-sheet. With target-aimed therapy, EPO becomes effective again.

erythropoetin - kidney - anemia - dialysis - iron deficiency - hyperparathyreoidism - infection - inflammation

Literatur

• 1 Bradbury BD, Danese MD, Gleeson M, Critchlow CW.. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL.  Clin J Am Soc Nephrol. 2009;  4 630-637
• 2 Zhang Y, Thamer M, Stefanik K et al.. Epoetin requirements predict mortality in hemodialysis patients.  Am J Kidney Dis. 2004;  44 866-876
• 3 Kausz AT, Solid C, Pereira BJ et al.. Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease?.  Am J Kidney Dis. 2005;  45 136-147
• 4 IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000.  Am J Kidney Dis. 2001;  37 182-238
• 5 Drueke TB, Locatelli F, Clyne N et al.. Normalization of hemoglobin level in patients with chronic kidney disease and anemia.  N Engl J Med. 2006;  355 2071-2084
• 6 Locatelli F, Aljama P, Barany P et al.. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.  Nephrol Dial Transplant. 2004;  19 (S 02) 1-47
• 7 Hutchinson FN, Jones WJ.. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease.  Am J Kidney Dis. 1997;  29 651-657
• 8 Loge JP, Lange RD, Moore CV.. Characterization of the anemia associated with chronic renal insufficiency.  Am J Med. 1958;  24 4-18
• 9 Silverberg DS, Iaina A, Peer G et al.. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.  Am J Kidney Dis. 1996;  27 234-238
• 10 Erslev AJ, Besarab A.. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure.  Kidney Int. 1997;  51 622-630
• 11 Eschbach JW.. Iron requirements in erythropoietin therapy.  Best Pract Res Clin Haematol. 2005;  18 347-361
• 12 Fernandez-Rodriguez AM, Guindeo-Casasus MC, Molero-Labarta T, Dominguez-Cabrera C, Hortal-Casc L n, Perez-Borges P, Vega-Diaz N, Saavedra-Santana P, Palop-Cubillo L.. Diagnosis of iron deficiency in chronic renal failure.  Am J Kidney Dis. 1999;  34 508-513
• 13 Kaufman JS, Reda DJ, Fye CL et al.. Diagnostic value of iron indices in hemodialysis patients receiving epoetin.  Kidney Int. 2001;  60 300-308
• 14 Danielson B.. R-HuEPO hyporesponsiveness -- who and why?.  Nephrol Dial Transplant. 1995;  10 (S 02) 69-73
• 15 Drueke TB.. R-HuEPO hyporesponsiveness -- who and why?.  Nephrol Dial Transplant. 1995;  10 (S 02) 62-68
• 16 Goicoechea M, Martin J, de Sequera P et al.. Role of cytokines in the response to erythropoietin in hemodialysis patients.  Kidney Int. 1998;  54 1337-1343
• 17 Gunnell J, Yeun JY, Depner TA, Kaysen GA.. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients.  Am J Kidney Dis. 1999;  33 63-72
• 18 Lopez-Gomez JM, Perez-Flores I, Jofre R et al.. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance.  J Am Soc Nephrol. 2004;  15 2494-2501
• 19 Alscher DM, Mettang T.. Procalcitonin in peritoneal dialysis--a useful marker of inflammation?.  Perit Dial Int. 2005;  25 441-444
• 20 Roberts TL, Obrador GT, St WL Peter et al.. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients.  Kidney Int. 2004;  66 2429-2436
• 21 Rao DS, Shih MS, Mohini R.. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia.  N Engl J Med. 1993;  328 171-175
• 22 Klemm A, Sperschneider H, Lauterbach H, Stein G.. Is folate and vitamin B12 supplementation necessary in chronic hemodialysis patients with EPO treatment?.  Clin Nephrol. 1994;  42 343-345
• 23 Zachee P, Chew SL, Daelemans R, Lins RL.. Erythropoietin resistance due to vitamin B12 deficiency. Case report and retrospective analysis of B12 levels after erythropoietin treatment.  Am J Nephrol. 1992;  12 188-191
• 24 Casadevall N, Dupuy E, Molho-Sabatier P et al.. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia.  N Engl J Med. 1996;  334 630-633
• 25 Casadevall N, Nataf J, Viron B et al.. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.  N Engl J Med. 2002;  346 469-475
• 26 McKoy JM, Stonecash RE, Cournoyer D et al.. Epoetin-associated pure red cell aplasia: past, present, and future considerations.  Transfusion. 2008;  48 1754-1762
• 27 Macdougall IC, Rossert J, Casadevall N et al.. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.  N Engl J Med. 2009;  361 1848-1855
• 28 Tomson CR, Edmunds ME, Chambers K et al.. Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure.  Nephrol Dial Transplant. 1992;  7 817-821
• 29 Griffing GT, Melby JC.. Enalapril (MK-421) and the white cell count and haematocrit.  Lancet. 1982;  1 1361
• 30 Fyhrquist F, Karppinen K, Honkanen T et al.. High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril.  J Intern Med. 1989;  226 257-260
• 31 Kamper AL, Nielsen OJ.. Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy.  Scand J Clin Lab Invest. 1990;  50 611-618
• 32 Kaiser L, Schwartz KA.. Aluminum-induced anemia.  Am J Kidney Dis. 1985;  6 348-352
• 33 Ifudu O, Feldman J, Friedman EA.. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.  N Engl J Med. 1996;  334 420-425
• 34 Movilli E, Cancarini GC, Zani R et al.. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.  Nephrol Dial Transplant. 2001;  16 111-114
• 35 Locatelli F, Andrulli S, Pecchini F et al.. Effect of high-flux dialysis on the anaemia of haemodialysis patients.  Nephrol Dial Transplant. 2000;  15 1399-1409
• 36 Richardson D, Lindley EJ, Bartlett C, Will EJ.. A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response.  Am J Kidney Dis. 2003;  42 551-560
• 37 Opatrny Jr. K, Reischig T, Vienken J et al.. Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis.  Artif Organs. 2002;  26 181-188
• 38 Locatelli F, Andrulli S, Memoli B et al.. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients.  Nephrol Dial Transplant. 2006;  21 991-998
• 39 Hurot JM, Cucherat M, Haugh M, Fouque D.. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review.  J Am Soc Nephrol. 2002;  13 708-714
• 40 Priyadarshi A, Shapiro JI.. Erythropoietin resistance in the treatment of the anemia of chronic renal failure.  Semin Dial. 2006;  19 273-278

Korrespondenz